• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Lung cancer mortality reduction linked to improvements in targeted therapies

bySamuel ChanandDeepti Shroff Karhade
August 12, 2020
in Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this retrospective cohort study, there was an observed decrease in mortality in non-small-cell lung cancer patients that corresponded with the approval of targeted therapies

2. The improved mortality of small cell lung cancer was not driven by treatment advancement but rather a decrease in the incidence

Evidence Rating Level: 2 (Good)

Study Rundown: Lung cancer is the deadliest cancer in the United States. It can be divided into two histological subtypes: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Using the U.S. Surveillance, Epidemiology, and End Results (SEER) database, the authors in this study analyzed mortality trends attributed to the specific histological subtype of lung cancer termed incidence-based mortality. For men and women with NSCLC, incidence and incidence-based mortality decreased, with a greater mortality decrease from 2013-2016 corresponding with an improvement in survival from diagnosis. For SCLC, incidence and incidence-based mortality decreased but with no improvement in survival from diagnosis. Notably, the authors point out that EGFR targeted therapies were approved in 2013 which corresponds to the increase in survival in NSCLC. There should be caution in the interpretation in the study’s suggestion that the survival benefit is entirely driven by targeted therapies as there is no direct data on the number of patients treated with EGFR targeted therapies right after 2013. However, the results of these study are generalizable given that it encompassed diverse demographics which showed consistent trends across race and gender subgroups and adequate follow-up data.

Click here to read the study, published today in NEJM

Relevant Reading: Updated statistics of lung and bronchus cancer in United States (2018)

In-Depth [retrospective cohort]: In this retrospective cohort study, lung cancer incidence and lung cancer linked deaths were analyzed in the SEER cancer registry from 2001 to 2016. For NSCLC, in men, the annual incidence decreased by 1.9% from 2001 to 2008, and then by 3.1% from 2008 to 2016. Incidence-based mortality decreased by 3.2% annually from 2006 to 2013 and then decreased by 6.3% from 2013 to 2016. Among women, 2001-2006 incidence did not change significantly, while from 2006-2013 incidence decreased by 1.5% annually. Incidence-based mortality decreased by 2.3% from 2006 to 2014, and then by 5.9% from 2014-2016. 2-year survival improved from 35% in 2001 to 44% in 2014 for women and went from 25% to 35% for men. For SCLC from 2001-2016, in men, the incidence decreased by 3.6%, while incidence-based mortality decreased by 4.3%. For women, the incidence decreased by 2.7% and incidence-based mortality decreased by 3.7%. 2-year survival from 2001 vs. 2016 was 12% and 11% for men and 14% and 17% for women. Taken together, these results indicated that mortality decreases in NSCLC were likely driven by improved survival, and for SCLC, it was mainly driven by decreased incidence.

RELATED REPORTS

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: EGFR inhibitorlung cancernon-small cell lung cancer (NSCLC)
Previous Post

Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized controlled trial

Next Post

#VisualAbstract: Metformin for survivors of pediatric brain tumors

RelatedReports

#VisualAbstract: Increased physical activity is a long-term protective factor for dementia
StudyGraphics

#VisualAbstract: Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 18, 2022
Age and number of islet autoantibodies associated with diabetes risk
Oncology

The antibody drug conjugate MRGOO3 is a promising for use in EGFR-expressing cancers

May 16, 2022
Dacomitinib may be effective in EGFR-associated lung cancer
Chronic Disease

Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer

May 9, 2022
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Next Post
#VisualAbstract: Hydroxychloroquine with/without azithromycin for mild to moderate SARS-CoV-2

#VisualAbstract: Metformin for survivors of pediatric brain tumors

Pharmacist-led educational intervention decreases inappropriate medications for older adults

Afabicin noninferior to vancomycin and linzeolid for treatment of staphylococcal infections

#VisualAbstract: Serum antibody testing for SARS-CoV-2

#VisualAbstract: Nemolizumab for pruritis in atopic dermatitis patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
  • High pediatric sequential organ failure assessment (pSOFA) score may predict hospital mortality in emergency department setting
  • #VisualAbstract: Increased physical activity is a long-term protective factor for dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.